On June 24, 2026, International Low Grade Glioma Registry founder and attending neurosurgeon Dr. Elizabeth B. Claus discussed preliminary findings from the Registry's germline testing study for cancer genes in people with glioma. Watch to learn about what these findings may mean for patients and their family members, and how to participate in the study.

All Registry/OPTIMUM participants are now eligible to participate in the clinical-level germline testing study, but enrollment requires a new consent. If you are interested, please contact us at glioma@yale.edu.